-
New adjuvant new crown pneumonia epidemic Miao ReCOV updated a number of overseas clinical research progress
Time of Update: 2023-01-06
3. ReCOV primary immunization and sequential booster immunization can induce high levels of neutralizing antibodies against Omicron variants.
3. ReCOV primary immunization and sequential booster immunization can induce high levels of neutralizing antibodies against Omicron variants.
-
Sartorius Double 11 Promotion Consumables Special Offer Full of Gifts
Time of Update: 2023-01-06
11. 10-11. 11Double 11 promotion is about to end, and it's too late if you don't stock up on consumables Sartorius brand feedback day consumables promotion double benefits Ultrafiltration, filtration
-
77.2% of patients achieved objective remission, and the results of the new drug QL1706 for the treatment of cervical cancer with Qilu combination antibody were announced
Time of Update: 2023-01-06
This study aimed to assess the safety and efficacy of QL1706 in combination with paclitaxel-cisplatin/carboplatin plus or without bevacizumab for the first-line treatment of relapsed or metastatic cervical cancer.
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2023-01-06
At the 5th China International Import Expo, Novo Nordisk (Shanghai) Pharmaceutical Trading Co. , Ltd. (hereinafter referred to as "Novo Nordisk Shanghai") signed a strategic cooperation agreement wit
-
Abbisko will present ABSK021 Phase IB clinical study data at the 2022 CTOS Annual Meeting
Time of Update: 2023-01-06
This development is a Phase IB study on the excellent antitumor activity and good safety profile of ABSK021 in the treatment of advanced gangsheath giant cell tumor (TGCT), and will be presented in poster format at the Annual Meeting.
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2023-01-06
At the 5th China International Import Expo, Novo Nordisk (Shanghai) Pharmaceutical Trading Co. , Ltd. (hereinafter referred to as "Novo Nordisk Shanghai") signed a strategic cooperation agreement wit
-
Abbisko will present ABSK021 Phase IB clinical study data at the 2022 CTOS Annual Meeting
Time of Update: 2023-01-06
This development is a Phase IB study on the excellent antitumor activity and good safety profile of ABSK021 in the treatment of advanced gangsheath giant cell tumor (TGCT), and will be presented in poster format at the Annual Meeting.
-
Ascletis announces that the clinical trial application for the viral polymerase inhibitor ASC10 monkeypox indication has been approved by the US Food and Drug Administration
Time of Update: 2023-01-05
Ascletis has filed several patent applications worldwide for ASC10 and its use in the treatment of viral diseases, including monkeypox virus infection.
Ascletis has filed several patent applications worldwide for ASC10 and its use in the treatment of viral diseases, including monkeypox virus infection.
-
Officially included in the breakthrough therapy variety! Remegen Taitacept was again recognized for myasthenia gravis
Time of Update: 2023-01-05
About Tatacept Tatanercept is an antibody fusion protein drug molecule invented and designed by Professor Fang Jianmin, CEO and Chief Scientific Officer of Remegen Biologics, which inhibits the overexpression of two cytokines, BLyS and APRIL, and prevents the abnormal differentiation and maturation of B cells, thereby treating B-cell-mediated systemic lupus erythematosus and other autoimmune diseases.
-
New research reveals sore throat, antibiotic overuse driving the third leading cause of death worldwide
Time of Update: 2023-01-05
”A new global study launched during World Antimicrobial Awareness Week (WAAW, 18-24 November) shows that high reliance on antibiotics to treat respiratory conditions such as sore throats is driving up antibiotic resistance, the third leading cause of death globally, linked to 4.
-
The latest data of GT19715, a new C-Myc/GSPT1 dual-target degrader, was presented at ASH 2022 in an oral presentation
Time of Update: 2023-01-05
Dr. Youzhi Tong, Founder, Chairman and CEO of Pioneer Pharmaceuticals, said, "We are very pleased that the latest results of the new c-Myc/GSPT1 dual-target degrader GT19715 have been selected as an oral presentation for this year's ASH Annual Meeting, which demonstrates the recognition of the therapeutic potential of GT19715 by the international hematology community.
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-05
Dr. Patricia Keegan, Chief Medical Officer of Junshi Biologics, said, "This month, we submitted our marketing applications for teripulimab to two major European regulatory agencies, which reflects the company's strong determination and efficient execution to promote innovative drugs for the benefit of patients around the world.
-
Corning Jerry will present the latest results of bispecific antibody products at the 2022 San Antonio Breast Cancer Congress
Time of Update: 2023-01-05
m. (CST) Display form: poster Poster topic: KN026 in combination with docetaxel for neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: a single-arm, multicenter, phase II study Poster number: OT2-16-04 Corresponding author: Professor Wu Jiong, Cancer Hospital of Fudan University Published: December 7, 2022, 5:00- 6:15pm (CST) About KN046 KN046 is a PD-L1/CTLA-4 bispecific antibody developed by Corning Jerry, with independent intellectual property rights.
-
TD Biologics announces the latest clinical trial progress of the CFI-402257 and CFI-400945 programs at the 2022 San Antonio Breast Cancer Conference
Time of Update: 2023-01-05
" " Information on the four abstracts: SUMMARY: Recent advances in the Phase 1 clinical trial of CFI-402257 (oral TTK inhibitor) in patients with advanced solid tumors in the HER2-negative breast cancer expansion cohort Poster ID： P6-10-13 Session: Therapeutics: Therapeutic Strategies - New Targets and Targeted Drugs Date: Friday, December 9, 2022 Time: 7:00 a.
-
Alphyn completed Phase 2a clinical trial cohort first recruitment
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Alphyn Biologics, a clinical-stage dermatology company developing the first multi-target therapeutic, today announced the completion of cohort 1 enrollment for the Phase 2a clinical trial of AB-101a.
-
Reindeer Bio published the world's first clinical trial results of BCMA-CART for the treatment of autoimmune diseases in the journal Nature
Time of Update: 2023-01-05
This study is an open-label exploratory clinical study (NCT04561557) initiated by a researcher to evaluate the safety and efficacy of Iquilencel cell infusion in the treatment of relapsed/refractory antibody-mediated neuropathic inflammatory diseases (NCT04561557), conducted by the team of Professor Wang Wei of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology.
-
BioVaxys sabeivirus disease interim data results announced
Time of Update: 2023-01-05
(CSE:BIOV)(FRA:5LB)(OTCQB:BVAXF)("BioVaxys" or the "Company") is pleased to announce that the interim results of its ongoing BVX-1021 preclinical study have shown excellent tolerability with no side effects or notable clinical observations 。 BVX-1021 is a strain developed by the Company for SARS-CoV-1 ("SARS1") and is currently evaluating this vaccine in collaboration with Ohio State University to develop the pansabeivirus vaccine.
-
Cellular molecule through peptide design
Time of Update: 2023-01-05
To design efficient cell-penetrating peptides, numerous parameters including charge, guanidine group, chirality, hydrophobicity, and aromatics, and their interactions require further study.
To design efficient cell-penetrating peptides, numerous parameters including charge, guanidine group, chirality, hydrophobicity, and aromatics, and their interactions require further study.
-
Mabwell's innovative drug 9MW3011 injection was approved by the FDA for clinical trials
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Mabwell Biologics (688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell Biologics (688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell Biologics (688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell Biologics (688062.
9MW3011 is an innovative target monoclonal antibody independently developed by Mabwell's San Diego Innovation R&D Center in the United States, which is a class 1 therapeutic biological product.
-
This pharmaceutical company has another drug review! Since the second half of the year, a total of 3 varieties have been evaluated
Time of Update: 2023-01-05
According to the announcement, isoniazid tablets (specifications: 300mg, 100mg) of Mingxing Pharmaceutical, a wholly-owned subsidiary of the company, have passed the consistency evaluation of the quality and efficacy of generic drugs.
